Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies

Jing Chang1, Haiyong Peng1, Brian C. Shaffer2, Sivasubramanian Baskar2, Ina C. Wecken1, Matthew G. Cyr1, Gustavo J. Martinez3, Jo Soden4, Jim Freeth4, Adrian Wiestner5, and Christoph Rader1,2

Abstract

Although the 5-year survival rate of chronic lymphocytic leukemia (CLL) patients has risen to >80%, the only potentially curative treatment is allogeneic hematopoietic stem cell transplantation (alloHSCT). To identify possible new monoclonal antibody (mAb) drugs and targets for CLL, we previously developed a phage display–based human mAb platform to mine the antibody repertoire of patients who responded to alloHSCT. We had selected a group of highly homologous post-alloHSCT mAbs that bound to an unknown CLL cell surface antigen. Here, we show through next-generation sequencing of cDNAs encoding variable heavy-chain domains that these mAbs had a relative abundance of ~0.1% in the post-alloHSCT antibody repertoire and were enriched ~1,000-fold after three rounds of selection on primary CLL cells. Based on differential RNA-seq and a cell microarray screening technology for discovering human cell surface antigens, we now identify their antigen as Siglec-6. We verified this finding by flow cytometry, ELISA, siRNA knockdown, and surface plasmon resonance. Siglec-6 was broadly expressed in CLL and could be a potential target for antibody-based therapeutic interventions. Our study reaffirms the utility of post-alloHSCT antibody drug and target discovery. Cancer Immunol Res; 6(9); 1008–13. ©2018 AACR.

Introduction

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the United States, with a lifetime risk of ~0.6% and an incidence of ~20,000 cases annually (https://seer.cancer.gov/statfacts/html/clyl.html; ref. 1). Chemoimmunotherapy and small-molecule kinase inhibitors have increased the 5-year survival rate to >80%. Despite this, allogeneic hematopoietic stem cell transplantation (alloHSCT) has remained the only potentially curative treatment of CLL. Although alloHSCT is not available for most patients and is associated with high morbidity and mortality (2), it underscores the potency of immunotherapy in eradicating CLL and provides an incentive to identify the underlying targets and mechanisms (3). Based on the hypothesis that post-alloHSCT antibodies contribute to the graft-versus-leukemia (GVL) response (4), and the detection of serum antibody titers to CLL cell surface antigens following alloHSCT, we developed a concerted antibody drug and target discovery strategy (5, 6). Here, we report the identification of Siglec-6 as a target of post-alloHSCT antibodies and confirm its expression in CLL.

Materials and Methods

Cell lines and primary cells

Cell lines MEC-1 (DSMZ #ACC 497) and U937 (ATCC #CRL-1593.2) were newly purchased and used within three passages after thawing without additional cell line authentication and mycoplasma testing. The cell line MEC-1 was derived from the cell line MEC1 by FACS using a BD FACSVantage instrument following staining with chemically biotinylated BiotinTag Micro Biotinylation Kit (Sigma-Aldrich) JML-1 IgG1 (5) and PE-conjugated streptavidin, cloned by limiting dilution, cryopreserved, and used as described for its parental cell line. Cryopreserved treatment-naïve CLL peripheral blood mononuclear cells (PBMC) were derived from a natural history study at the NIH Clinical Center registered as NCT00923507 at www.clinicaltrials.gov. The study was approved by the institutional review boards of the NIH Clinical Center and The Scripps Research Institute and written informed consent was obtained in accordance with the Declaration of Helsinki.

1, 2Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida. 3Experimental Transplantation and Immunology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. 4Genomics Core, The Scripps Research Institute, Jupiter, Florida. 5Retrogenix Ltd, High Peak, United Kingdom.

Current address for B.C. Shaffer: Memorial Sloan Kettering Cancer Center, Bethesda, Maryland; current address for S. Baskar, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; and current address for G.J. Martinez, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois.

Corresponding Author: Christoph Rader, Department of Immunology and Microbiology, The Scripps Research Institute, 130 Scripps Way #2C1, Jupiter, FL 33458. Phone: 561-228-2053; E-mail: crader@scripps.edu

doi: 10.1158/2326-6066.CIR-18-0102
©2018 American Association for Cancer Research.
Next-generation sequencing

\[ V_L \]
\[
\begin{align*}
FR1 & : DIQMTQSPSSLSASVQPRVTITC \\
CDR1 & : RASQISSSYLN \\
FR2 & : WYQQKKPGKAPKLIIY \\
CDR2 & : AAASSLOS \\
FR3 & : GVPFSRSSGGSTDFLTITSSQPEDFATYYC \\
CDR3 & : QQQSTPFT \\
FR4 & : FPGPTKVDIK
\end{align*}
\]

\[ V_H \]
\[
\begin{align*}
FR1 & : KVQLESGGGLQVRQPSLRLSCAASGFTFD \\
CDR1 & : DYGMM \\
FR2 & : VWRRQAPGKGLEWV \\
CDR2 & : GISWNSGSIYADSVKG \\
FR3 & : RFTISRDNKLTLVLQMNSLRAEDTAVYCAR \\
CDR3 & : GGGTIDI \\
FR4 & : WGGTMTVTVSS
\end{align*}
\]

Figure 1.

NGS analysis of alloHSCT Fab-phage library selection. A, Relative abundance of the three most frequent HCDR3 amino acid sequences before selection and the most frequent HCDR3 motif after selection of the alloHSCT Fab-phage library by three rounds of panning on CLL cells. VGR stands for VGRLQYDYYFDS; YGM stands for YGMDV; THI stands for THIVVPGPGFGLD; GGQ stands for GGQTIDI (the HCDR3 of JML-1). Blue and red columns show the respective relative abundance before and after selection. The values on top of the paired columns give the log_2 enrichment.

B, Amino acid sequences of the variable-light (VL) and heavy-chain domains (VH) of selected post-alloHSCT Fab JML-1 (U.S. Patent 8,877,199). FR and CDR denote framework regions and complementarity-determining regions, respectively.

2100 Bioanalyzer, respectively. Samples with an RNA integrity number \( \geq 9 \) were sequenced using an Illumina NextSeq 500 system at a targeted depth of 20 million paired-end reads and processed and analyzed with TopHat 2.0.9, HTSeq 0.6.1, and DESeq2 software. Differentially expressed genes encoding transmembrane proteins were then identified.

Retrogenix cell microarray

Primary and confirmatory screens with 20 \( \mu \)g/mL JML-1 IgG1 (5) were carried out exactly as described (8) based on a collection of 4,336 human transmembrane proteins.

Flow cytometry

The binding of 1 \( \mu \)g/mL of chemically biotinylated JML-1 IgG1 and a chemically biotinylated human IgG1 isotype control to MEC1, MEC1-002, and U937 cell lines was detected with PE-conjugated streptavidin (BD Biosciences) by flow cytometry using a BD LSR II instrument. CLL PBMCs were stained using 1 \( \mu \)g/mL of the commercial mouse anti-human Siglec-6 mAb 767329 (R&D Systems) followed by Alexa Fluor 647-conjugated goat anti-mouse IgG PAbs and, separately, 1 \( \mu \)g/mL of chemically biotinylated JML-1 IgG1 followed by PE-conjugated streptavidin. The difference of mean fluorescence intensity (ΔMFI) values from the two separate stainings was plotted to analyze their Pearson correlation coefficient \( r^2 \) using GraphPad Prism software version 7.

Differential RNA-seq

RNA was isolated with a PureLink RNA Mini Kit (Thermo Fisher Scientific). RNA concentration and quality were determined using a NanoDrop spectrophotometer and an Agilent 2100 Bioanalyzer, respectively.Samples with an RNA integrity number \( \geq 9 \) were sequenced using an Illumina NextSeq 500 system at a targeted depth of 20 million paired-end reads and processed and analyzed with TopHat 2.0.9, HTSeq 0.6.1, and DESeq2 software. Differentially expressed genes encoding transmembrane proteins were then identified.

ELISA

The binding of 1 \( \mu \)g/mL of chemically biotinylated JML-1 IgG1 and a chemically biotinylated human IgG1 isotype control to plate-bound human CD22-Fc, CD33-Fc (blue), Siglec-6-Fc (red),...
and Siglec-8-Fc (purple; all from R&D Systems) was detected using HRP-conjugated streptavidin. HRP-conjugated goat anti-human Fc pAbs (Jackson ImmunoResearch) were used to confirm the presence of the plate-bound Fc fusion proteins.

Surface plasmon resonance

Surface plasmon resonance (SPR) studies were carried out on a Biacore X100 instrument as described (8). In brief, SPR sensorgrams were obtained for the binding of JML-1 Fab to Siglec-6-Fc captured on a goat anti-human Fc-coated CM5 chip (GE Healthcare). JML-1 Fab was injected at five different concentrations in the following order: 6.25 nmol/L, 12.5 nmol/L, 25 nmol/L, 50 nmol/L, 100 nmol/L, and again 6.25 nmol/L. The six SPR sensorgrams were used to calculate k_{on}, k_{off}, and K_D.

siRNA knockdown

For knockdown studies, 1 × 10^8 MEC1-002 cells in a 12-well tissue culture plate were incubated with 1 μmol/L of Accell SIGLEC6-targeting or control siRNAs (both from Dharmacon) for 72 hours and then analyzed by flow cytometry using chemically biotinylated JML-1 IgG1 in conjunction with PE-conjugated streptavidin and mouse anti-human Siglec-6 mAb 767329 in conjunction with Alexa Fluor 647-conjugated goat anti-mouse IgG pAbs. Three independent experiments that were carried out are shown as mean ± SD values and analyzed for significance by two-way ANOVA (***, P < 0.0001).

Figure 2.

Discovery of Siglec-6 as the antigen of mAb JML-1. A, The binding of biotinylated JML-1 IgG1 (red) and a biotinylated human IgG1 isotype control (light blue) to MEC1 (left), MEC1-002 (middle), and U937 (right) cell lines was detected with PE-conjugated streptavidin by flow cytometry. A representative out of three independent experiments is shown. B, List of the top 10 RNA-seq hits of genes encoding human transmembrane proteins with differential expression in MEC1 and MEC1-002 cells. Of these, nine were present in the Retrogenex chip microarray of a collection of 4,336 human transmembrane proteins and one (Siglec-6 encoded by SIGLEC6) was detected with JML-1 IgG1 in primary and confirmatory screens. C, MEC1-002 cells were incubated with siRNA targeting SIGLEC6 (red) or a control siRNA (blue) and then analyzed by flow cytometry for binding by either biotinylated JML-1 IgG1 in conjunction with PE-conjugated streptavidin or mouse anti-human Siglec-6 mAb 767329 in conjunction with Alexa Fluor 647-conjugated goat anti-mouse IgG pAbs. Three independent experiments that were carried out are shown as mean ± SD values and analyzed for significance by two-way ANOVA (***, P < 0.0001).
Results and Discussion

Using reverse-transcribed mRNA from cryopreserved PBMCs prepared 6 months after alloHSCT from a CLL patient, who eventually achieved a complete response, we previously generated a fully human Fab library using our phage display vector pC3C (5). We selected the library by three rounds of whole-cell panning using primary CLL cells from an untreated and unrelated CLL patient and identified a group of highly homologous post-alloHSCT mAbs with identical third complementarity-determining regions of heavy and light chain (HCDR3 and LCDR3, respectively), which indicated a shared CLL cell surface antigen (5). To determine the abundance of these mAbs in the post-alloHSCT antibody repertoire before selection, we sequenced by NGS the cDNA fragments encoding variable heavy-chain domain (VH) in the library (Fig. 1A). Of 402,319 sequenced VH with at least one identical repeat, 373 (0.093%) contained the defining HCDR3 amino acid sequence GGQTIDI that we reported previously (5). A relative abundance of ∼0.1% on the protein level would correspond to serum antibodies at ∼10 μg/mL, a concentration high enough to contribute to the primary CLL cell–directed post-alloHSCT serum antibody titers we detected (5). After selection, the abundance of GGQTIDI increased to 91.5% (1,107,350 of 1,209,577 sequenced VH; Fig. 1A).

The strongest binder in the panel of post-alloHSCT Fabs was converted to IgG1 and named JML-1 (Fig. 1B; ref. 5). Extensive attempts to identify the antigen of mAb JML-1 by flow cytometry using mouse anti-human Siglec-6 mAb 767329 followed by Alexa Fluor 647-conjugated goat anti-mouse IgG pAbs and, separately, biotinylated JML-1 IgG1 followed by PE-conjugated streptavidin. ∆MFI denotes the staining above background staining with corresponding isotype controls. A representative one of the one to two independent experiments for each sample is shown. The ∆MFI values from the two separate stainings of each of the 16 primary CLL PBMCs were plotted to analyze their Pearson correlation coefficient r².
immunoprecipitation and mass spectrometry as well as by cDNA expression cloning failed. These approaches were complicated by the fact that our initial study detected the antigen only on primary CLL cells and not on a large panel of B-cell lines we tested (5). However, we noted that a subpopulation of the CLL cell line MEC1 (11) was stained by mAb JML-1 (Fig. 2A). Using FACS, this subpopulation was enriched and designated MEC1-002 (Fig. 2A). Incubation of MEC1-002 with trypsin, but not with phosphatidylinositol-specific phospholipase C (PI-PLC), revealed loss of mAb JML-1 binding in correlation with incubation time. This suggested that the antigen was a transmembrane protein. A differential RNA-seq analysis of MEC1-002 versus MEC1 cells identified enriched mRNAs encoding transmembrane proteins in MEC1-002 cells (Fig. 2B). To narrow down this list with an independent approach, 4,336 human transmembrane proteins were screened with JML-1 IgG1 using a Retrogenix cell microarray (8). The reproducibly strongest signal in primary and confirmatory screens came from Siglec-6. None of the other transmembrane proteins identified by RNA-seq and present in the cell microarray assay were detected (Fig. 2B). Unlike any other human cell line we tested previously, the myeloid cell line U937, which is known to express Siglec-6 (12), was strongly bound by mAb JML-1 (Fig. 2A). When MEC1-002 cells were transfected with siRNA targeting SIGLEC6 mRNA, the detection by flow cytometry of both mAb JML-1 and commercial mouse anti-human Siglec-6, mAb 767329, was significantly silenced compared with MEC1-002 cells transfected with control siRNA (Fig. 2C).

To verify that Siglec-6 is indeed recognized by mAb JML-1, we used commercial Fc fusion proteins of CD22 (a.k.a. Siglec-2), CD33 (a.k.a. Siglec-3), Siglec-6, and Siglec-8. The latter three belong to the Siglec-3 family (13) and share 52% to 63% amino acid sequence identity in their extracellular domain (12, 14). JML-1 IgG1 strongly and exclusively bound to Siglec-6 in ELISA (Fig. 3A). Strong binding (K_D = 2.8 nmol/L) to immobilized Siglec-6 was also found for JML-1 Fab, as measured by SPR (Fig. 3B). In addition, reselection of the alloHSCT Fab-phage library by four rounds of panning on an immobilized recombinant Siglec-6-Fc fusion protein again yielded Fabs with the same HCDR3 and LCDR3 amino acid sequences as JML-1 (Fig. 1B) as predominant binders.

For further validation, we stained a panel of 16 treatment-naïve primary CLL PBMCs with (i) JML-1 IgG1 and (ii) mAb 767329 by flow cytometry (Fig. 3C). As we observed previously for a smaller set of primary CLL cells (5), the MFI revealed a wide range of Siglec-6 cell surface densities on the malignant B cells. The staining of mAbs JML-1 and 767329 correlated strongly (r^2 = 0.9097), further corroborating that Siglec-6 was the common antigen (Fig. 3D).

Like other Siglecs, Siglec-6 is characterized by a sialic acid binding site in the extracellular domain and an intracellular ITIM motif (13, 15), implying a role in cell adhesion, migration, and signaling, all of which could be attenuated by post-alloHSCT antibodies that contribute to the GVL response. Although the scarcity of post-alloHSCT serum and PBMCs sample collections has precluded us from examining Siglec-6 reactivity in additional CLL patients, our concerted antibody drug and target discovery strategy (i) unveiled Siglec-6 as a broadly expressed CLL cell surface antigen and (ii) delivered fully human anti-human Siglec-6 mAbs. The expression of SIGLEC6 mRNA and Siglec-6 protein in healthy individuals is highly restricted to the placenta, to mast cells, and to exhausted B cells (www.proteinatlas.org/ENSG00000105492-SIGLEC6/tissue; refs. 12, 16). Siglec-6 is not expressed on hematopoietic stem cells (17). Collectively, we found that Siglec-6 is broadly expressed in CLL and warrants interrogation as a candidate target for antibody-based immunotherapeutic interventions. Mining human antibody repertoires by whole-cell panning using phage display or other methods (18) provides a powerful means for antigen-agnostic selection of fully human mAbs. The approaches we used here for antigen identification support concerted antibody drug and target discovery.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: J. Chang, H. Peng, G.J. Martinez, C. Rader
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Chang, H. Peng, B.C. Shaffer, S. Baskar, I.C. Wecken, M.G. Cyt, G.J. Martinez, J. Soden, J. Freeth, A. Wiestner
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J. Chang, H. Peng, S. Baskar, G.J. Martinez, J. Soden, J. Freeth, C. Rader
Writing, review, and/or revision of the manuscript: J. Chang, H. Peng, B.C. Shaffer, S. Baskar, C. Rader
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Chang, H. Peng
Study supervision: J. Freeth, C. Rader

Acknowledgments
We thank Drs. Steven R. Head, Philipp Ondokhianian, and Shuli Kang from the Next Generation Sequencing and Microarray Core Facility of The Scripps Research Institute in La Jolla, CA, for acquiring and analyzing NGS data; and Dr. Pabalu Kanadharma, Wayra Navia, and Nicholas Bild from the Genomics Core of The Scripps Research Institute in Jupiter, FL, for acquiring and analyzing differential RNA-seq data. We also thank Marko Modric and Drs. Ivan Samija, Roger R. Boerli, Peter Steinberger, and Christopher S. Hourigan for conducting earlier attempts to discover the antigen of mAb JML-1. This is manuscript 29629 from The Scripps Research Institute. This study was supported by NIH grant U01 CA174844 and by the Intramural Research Programs of NCIC, NIH and NHLBI, NIH.

Received February 19, 2018; revised April 27, 2018; accepted June 28, 2018; published first July 6, 2018.

References

1012 Cancer Immunol Res; 6(9) September 2018 Cancer Immunology Research


Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies

Jing Chang, Haiyong Peng, Brian C. Shaffer, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2326-6066.CIR-18-0102

Cited articles
This article cites 18 articles, 5 of which you can access for free at:
http://cancerimmunolres.aacrjournals.org/content/6/9/1008.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerimmunolres.aacrjournals.org/content/6/9/1008.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.